Understand the source comparison
Best Peptides for Libido Enhancement Research: Mechanism Comparison
PT-141 (Bremelanotide) Melanocortin receptor agonism → central arousal initiation MC3R, MC4R (hypothalamus) Subcutaneous injection 45–60 minutes 1.75mg subcutaneous Strongest Phase III data for central arousal effects; works independently of hormone status Kis
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (Bremelanotide)
- Melanocortin receptor agonism → central arousal initiation
- MC3R, MC4R (hypothalamus)
- Subcutaneous injection
- 45–60 minutes
- 1.75mg subcutaneous
- Strongest Phase III data for central arousal effects; works independently of hormone status
- Kisspeptin-10
- GnRH neuron activation → pulsatile LH/FSH release
- KISS1R (hypothalamic GnRH neurons)
- Intravenous infusion
- 20–30 minutes
- 1–4 nmol/kg IV
- Best evidence for HPG axis restoration; requires intact gonadal function to produce testosterone effects
- Oxytocin
- Neuropeptide signaling → dopamine potentiation in limbic regions
- OXTR (amygdala, nucleus accumbens)
- Intranasal spray
- 30–45 minutes
- 24–40 IU intranasal
- Context-dependent effects; enhances partner-specific arousal and emotional intimacy but not arousal de novo
- Melanotan II
- Melanocortin receptor agonism (broader spectrum than PT-141)
- MC1R, MC3R, MC4R, MC5R
- 60–90 minutes
- 0.5–1mg subcutaneous
- Less selective than PT-141; significant MC1R binding causes skin pigmentation as side effect
- Vasopressin (AVP)
- V1a receptor activation → territorial and bonding behaviors
- V1aR (hypothalamus, amygdala)
- 20–40 IU intranasal
- Gender-dimorphic effects; stronger pair-bonding effects in males than females